Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | SNCA | P37840 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | ADK | P55263 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190994 | 0.88 | ACHE (0.42) | MAPTAPPSNCAACHETHRB | |
| SCHEMBL13007728 | 0.86 | ACHE (0.41) | MAPTAPPSNCAACHETHRB | |
| SCHEMBL190671 | 0.86 | ACHE (0.42) | MAPTAPPSNCAACHETHRB | |
| SCHEMBL7478182 | 0.85 | ALDH1A1 (0.44) | MAPTAPPSNCAMAPK1SMN1; SMN2 | |
| SCHEMBL190557 | 0.83 | ACHE (0.48) | MAPTAPPSNCAACHEGSK3B | |
| SCHEMBL7468750 | 0.83 | CASP3 (0.44) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7467559 | 0.82 | TSHR (0.58) | THRBMAPK1GSK3BADKSMN1; SMN2 | |
| SCHEMBL7473595 | 0.81 | SIRT2 (0.50) | MAPTAPPSNCAMEN1KMT2A | |
| SCHEMBL7474357 | 0.81 | CASP1 (0.53) | MAPTAPPSNCAACHEMEN1 | |
| SCHEMBL7470312 | 0.80 | ALDH1A1 (0.48) | MAPK1MEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814878-B1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7851480-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851480-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851480-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7557207-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557207-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557207-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| EP-1814878-A1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060167254-A1 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | US | disclosed |
| WO-2006068770-A1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167254-A1 | Spiro 2,4-pyrimidinediamine compounds and their uses | SSB, SPHK2, PKD2 | MAPT 4264/4885APP 3360/4885SNCA 1404/4885 |
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | SSB, SPHK2, PKD2 | MAPT 4261/4885APP 3114/4885SNCA 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.